Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 17/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 17/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | PAK4 | O96013 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
| ▸ | CSF1R | P07333 | 1/20 | 0.40 |
| ▸ | RET | P07949 | 1/20 | 0.40 |
| ▸ | IGF1R | P08069 | 1/20 | 0.40 |
| ▸ | FLT1 | P17948 | 1/20 | 0.40 |
| ▸ | LTK | P29376 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.40 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.40 |
| ▸ | CLK2 | P49760 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1577362 | 0.77 | AURKA (0.47) | AURKAMAP4K4ABL1CSF1RRET | |
| SCHEMBL5676640 | 0.77 | PDE3B (0.53) | PDE3BPDE3AAURKADAPK3JAK2 | |
| SCHEMBL10298653 | 0.76 | PDE3B (0.45) | PDE3BPDE3AAURKA | |
| SCHEMBL9909697 | 0.75 | KDM4E (0.39) | PDE3BPDE3AAURKADAPK3JAK2 | |
| SCHEMBL22864137 | 0.74 | ADRB2 (0.45) | — | |
| SCHEMBL24139779 | 0.74 | IKBKB (0.46) | AURKADAPK3JAK2MAP4K4PAK4 | |
| SCHEMBL13975969 | 0.74 | IKBKB (0.43) | AURKADAPK3JAK2MAP4K4PAK4 | |
| SCHEMBL10308523 | 0.74 | PDE3B (0.54) | PDE3BPDE3AHCAR1 | |
| SCHEMBL84365 | 0.73 | PRKCI (0.53) | AURKADAPK3JAK2MAP4K4PAK4 | |
| SCHEMBL29397850 | 0.73 | PDE3B (0.45) | PDE3BPDE3AAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025918-A1 | KRAS G12D Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20240025918-A1 | KRAS G12D Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-8110687-B2 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-20110003806-A1 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-7777040-B2 | Certain substituted ureas, as modulators of kinase activity | CGI PHARMACEUTICALS, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003806-A1 | Heteroaryls and uses thereof | RICTOR, MTOR, AKT1S1 | PDE3B 1572/4885PDE3A 2568/4885AURKA 2058/4885 |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MAP3K20, MAP3K1, MAP3K5 | PDE3B 897/4885PDE3A 1210/4885AURKA 169/4885 |
| US-20240025918-A1 | KRAS G12D Inhibitors | KRAS, NRAS, HRAS | PDE3B 3893/4885PDE3A 3158/4885AURKA 3231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.